The combined treatment of canagliflozin and teneligliptin increased plasma GLP‐1 levels and improved glucose tolerance compared with either of the monotherapies in Zucker diabetic fatty rats.87 Treatment with empagliflozin, a highly potent and selective SGLT2 inhibitor, improved β cell function and insulin sensitivity thereby reducing prandial glycaemia in patients with T2DM in addition to enhanced GLP‐1 response although not significant88 (Table 4). The gene discussed is GCG; the disease is type 2 diabetes mellitus.